Safety and Immunogenicity of OVX836, a Nucleoprotein-Based Universal Influenza Vaccine, Co-Administered with Fluarix<sup>®</sup> Tetra, a Seasonal Hemagglutinin-Based Vaccine.

Vaccines (Basel) · 2025 · PMC12197426 · PMID 40573889

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

For the H1N1 and B strains, the differences were smaller and did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.

Safety and Immunogenicity of OVX836, a Nucleoprotein-Based Universal Influenza Vaccine, Co-Administered with Fluarix&lt;sup&gt;®&lt;/sup&gt; Tetra, a Seasonal Hemagglutinin-Based Vaccine.

The sentences

Safety and Immunogenicity of OVX836, a Nucleoprotein-Based Universal Influenza Vaccine, Co-Administered with Fluarix<sup>®</sup> Tetra, a Seasonal Hemagglutinin-Based Vaccine.